The radioligand therapy was linked with a significant increase in progression-free survival and a clinically relevant increase in overall survival in patients with midgut neuroendocrine tumours
Read More
A price cut has secured NHS funding for Advanced Accelerator Applications’ Lutathera as a treatment for some neuroendocrine tumours (NETs).
Read More
Novartis’ Afinitor and Pfizer’s Sutent have received backing from the National Institute for Health and Care Excellence as cost-effective treatment options for certain neuroendocrine tumours (NETs).
Read More
